Timothy Pigot - 22 Jan 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Reporting relationship: CHIEF COMMERCIAL OFFICER
Issuer ticker: JBIO
Reported as of: 22 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jan 2024, 18:00:32 UTC
Prior SEC filing: 08 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ George A. Eldridge, Attorney-in-Fact

Filing notes and source

Key filing fact

Timothy Pigot filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 24 Jan 2024.

Key facts

This page summarizes Timothy Pigot's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jan 2024, 18:00.

Change

Previous filing in this sequence was filed on 08 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVTE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,291
Date: 22 Jan 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVTE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +66,586
Change %
Price: $0.000000
Shares after: 66,586
Date: 22 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 66,586
Exercise price: $20.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).

Footnote F2

This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.